Live News EQUITY FLASH L impact Oct 30, 2026, 12:01 PM UTC Aer Therapeutics Reports Phase 2a Fexlamose Trial Results in COPD The company said a 90 mg daily nebulized dose of fexlamose did not improve trough F. SquawkNews Desk